Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

N/ACompletedNCT00115128

Amgen309 enrolled

Overview

The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

Study Type

OBSERVATIONAL

Enrollment

309

Conditions

Normal PBPC Donors

Interventions

filgrastimDRUG

Normal donors being treated with filgrastim for PBPC mobilization and collection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: - Eligible to be PBPC donor for allogeneic transplantation as determined by local institution Exclusion Criteria: - History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF

Outcomes

Primary Outcomes

Spleen fold change measured by ultrasound

Time frame: Before, during, and through 1 week post-PBPC mobilization and collection

Secondary Outcomes

Spleen change associations with filgrastim dose and hematologic variables

Time frame: Before, during, and through 1 week post-PBPC mobilization and collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.